Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging treatment landscape of non-muscle invasive bladder cancer.
Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, Briganti A, Curigliano G, Necchi A. Valenza C, et al. Among authors: necchi a. Expert Opin Biol Ther. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. Expert Opin Biol Ther. 2022. PMID: 35634893 Review.
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.
Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group. Necchi A, et al. BJU Int. 2018 Feb;121(2):252-259. doi: 10.1111/bju.14020. Epub 2017 Oct 12. BJU Int. 2018. PMID: 28940605
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, Roghmann F, Rouprêt M, Seiler R, Shariat SF, Qvick B, Babjuk M, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Hendricksen K, et al. Among authors: necchi a. Eur Urol Focus. 2019 Jul;5(4):681-688. doi: 10.1016/j.euf.2017.09.002. Epub 2017 Oct 23. Eur Urol Focus. 2019. PMID: 29074050
Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, Shariat SF, Xylinas E, Roghmann F; Young Academic Urologists′ Working Group on Urothelial Cancer of the European Association of Urology. von Landenberg N, et al. Among authors: necchi a. Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3. Urol Oncol. 2018. PMID: 29506940
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD. Necchi A, et al. Clin Genitourin Cancer. 2019 Feb;17(1):7-14.e3. doi: 10.1016/j.clgc.2018.09.008. Epub 2018 Sep 13. Clin Genitourin Cancer. 2019. PMID: 30292628 Free PMC article.
Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO).
Necchi A, Messina A, Briganti A. Necchi A, et al. Eur Urol. 2018 Nov;74(5):e107-e108. doi: 10.1016/j.eururo.2018.06.030. Epub 2018 Jul 4. Eur Urol. 2018. PMID: 30318068 No abstract available.
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F. Necchi A, et al. J Clin Oncol. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148. Epub 2018 Oct 20. J Clin Oncol. 2018. PMID: 30343614 Clinical Trial.
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Bandini M, et al. Among authors: necchi a. Eur Urol Oncol. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7. Eur Urol Oncol. 2019. PMID: 31200838 Free PMC article.
436 results